KNSA Kiniksa Pharmaceuticals, Ltd. - 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 29, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) at which a quorum was present. Holders of the Company’s Class A ordinary shares (“Class A Shares”) and Class B ordinary shares (“Class B Shares”) as of the close of business on April 6, 2026 (the “Record Date”) were entitled to notice of and to vote at the Annual Meeting. Each Class A Share was entitled to one vote per share and each Class B Share was entitled to ten votes per share.

The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 6, 2026. Each proposal below was duly passed by the Company’s shareholders at the Annual Meeting.

​

Proposal 1  - The re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2029 Annual Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office.

​

Nominee

​ ​ ​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

Stephen R. Biggar

​

37,474,114

​

11,999,916

​

13,825

​

4,425,771

G. Bradley Cole

​

48,299,818

​

1,174,991

​

13,046

​

4,425,771

Barry D. Quart

​

48,061,571

​

1,413,338

​

12,946

​

4,425,771

​

Proposal 2  - To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

53,857,053

​

48,432

​

8,141

​

0

​

Proposal 3  - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

53,857,126

​

48,355

​

8,145

​

0

​

Proposal 4  - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

53,890,585

​

12,498

​

10,543

​

0

​

Proposal 5  - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

53,611,179

​

2,032

​

300,415

​

0

​

Proposal 6  - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

48,353,142

​

1,104,811

​

29,902

​

4,425,771

​

Proposal 7  - To approve the Company’s UK Statutory Directors’ Remuneration Policy.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

48,633,937

​

824,799

​

29,119

​

4,425,771

​

​

​

Proposal 8  - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.

​

Votes FOR

​ ​ ​

Votes AGAINST

​ ​ ​

Votes ABSTAINED

​ ​ ​

Broker Non-Votes

48,145,082

​

1,334,278

​

8,495

​

4,425,771

​

​

​

​